HMDB0000012 | Deoxyuridine | 951-78-0 | | C9H12N2O5 | 228.202 228.074621504 | Not Available |
HMDB0000262 | Thymine | 65-71-4 | | C5H6N2O2 | 126.1133 126.042927446 | Not Available |
HMDB0000273 | Thymidine | 50-89-5 | | C10H14N2O5 | 242.2286 242.090271568 | Not Available |
HMDB0000300 | Uracil | 66-22-8 | | C4H4N2O2 | 112.0868 112.027277382 | Not Available |
HMDB0001351 | Deoxyribose 1-phosphate | 17210-42-3 | | C5H11O7P | 214.1104 214.024239218 | Not Available |
HMDB0001429 | Phosphate | 14265-44-2 | | H3O4P | 97.9952 97.976895096 | Not Available |
HMDB0014467 | Floxuridine | 50-91-9 | | C9H11FN2O5 | 246.1924 246.065199677 | - Ozawa S, Hamada M, Murayama N, Nakajima Y, Kaniwa N, Matsumoto Y, Fukuoka M, Sawada J, Ohno Y: Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver. Cancer Chemother Pharmacol. 2002 Dec;50(6):454-8. Epub 2002 Oct 26. [PubMed:12451471 ]
- Hara Y: [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. Gan To Kagaku Ryoho. 1984 Oct;11(10):2133-43. [PubMed:6237613 ]
- Sadahiro S, Otani Y, Oya K, Ike H, Shimada H, Yamaguchi S, Hiki Y, Fujita H, Mitomi T: Thymidine phosphorylase expression and effect of doxifluridine: a phase II study. Oncol Rep. 2001 Jul-Aug;8(4):753-8. [PubMed:11410777 ]
|
HMDB0014513 | Cidofovir | 113852-37-2 | | C8H14N3O6P | 279.187 279.062021707 | - De Clercq E: The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev. 2011 Jan;31(1):118-60. doi: 10.1002/med.20179. [PubMed:19844936 ]
|
HMDB0014576 | Trifluridine | 70-00-8 | | C10H11F3N2O5 | 296.1999 296.062006087 | - Temmink OH, Comijn EM, Fukushima M, Peters GJ: Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1491-4. [PubMed:15571283 ]
- Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K: Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep. 2004 Feb;11(2):381-7. [PubMed:14719072 ]
- Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL: Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9. doi: 10.1080/07357900802087242. [PubMed:18798063 ]
- Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM: Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006 Sep 15;107(6):1383-90. [PubMed:16902987 ]
- Temmink OH, Prins HJ, van Gelderop E, Peters GJ: The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer. 2007 Jan 15;96(1):61-6. Epub 2006 Dec 19. [PubMed:17179993 ]
- Bassler R, Buchwald W: [Experimental inflammation and fibrosis of the lung framework caused by ionizing rays. Light and electron microscopic studies]. Fortschr Geb Rontgenstr Nuklearmed. 1966 Feb;104(2):192-206. [PubMed:6010427 ]
|
HMDB0014684 | Fluorouracil | 51-21-8 | | C4H3FN2O2 | 130.0772 130.017855555 | - Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167. [PubMed:21332317 ]
|
HMDB0015233 | Capecitabine | 154361-50-9 | | C15H22FN3O6 | 359.3501 359.149263656 | - Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14. [PubMed:15132128 ]
- Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets. 2004 May;5(4):383-8. [PubMed:15134221 ]
- Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G: Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs. 2006 Aug;17(7):807-13. [PubMed:16926630 ]
- de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
- Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
- Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR: Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45. [PubMed:12481438 ]
- Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine]. Yakugaku Zasshi. 1999 Dec;119(12):881-97. [PubMed:10630095 ]
- Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
- Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
- Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-7. [PubMed:10755317 ]
- Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
|
HMDB0060393 | 5-Deoxyribose-1-phosphate | | | C5H11O7P | 214.1104 214.024239218 | Not Available |
HMDB0060406 | 5'-Deoxy-5-fluorouridine | | | C9H11FN2O5 | 246.1924 246.065199677 | Not Available |